2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
10:30 a.m. - 12:00 p.m.
MCCNO - 271-273
Treatment Considerations, Combination Therapy, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Measurable Residual Disease, CLL, Research, Clinical Research, Clinical Trials, Epidemiology, Study Population, Human, Adult
PAPER

814 Final Results of alliance A041202 demonstrate continued superiority of ibrutinib-containing regimens vs chemoimmunotherapy and durable remissions induced by ibrutinib in previously untreated older patients with chronic lymphocytic leukemia

Jennifer A. Woyach, MD, Gabriela Perez Burbano2, Cecelia R Miller, PhD3, Nyla Heerema, MD4, Weiqiang Zhao, MD, PhD5, Anna Wall6, Wei Ding7, Ehab Atallah, MD8, Nancy L. Bartlett, MD9, Danielle Brander, MD10, Paul M. Barr, MD11, Kerry A. Rogers, MD12, Sameer A. Parikh, MBBS13, Deborah Stephens, DO14, Jennifer R. Brown, MD, PhD15, Gerard Lozanski, MD16, James Stewart Blachly, MD17, Sreenivasa Nattam, MD18, Richard A. Larson, MD19, Harry P. Erba, MD20, Mark R. Litzow, MD21, Selina Luger, MD, FRCPC22, Carolyn Owen, MD23, Charles Kuzma24, Jeremy S. Abramson, MD25, Richard F. Little, MD26, Shira Dinner, MD27, Richard M. Stone, MD28, Geoffrey L. Uy, MD29, Wendy Stock, MD30, Sumithra Mandrekar, PhD31, John Byrd, MD32
1 The Ohio State University, Columbus, Ohio, United States
2 Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota, United States
3 The Ohio State University, Columbus, Ohio, United States
4 The Ohio State University, Columbus, Ohio, United States
5 The Ohio State University, Columbus, Ohio, United States
6 Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
9 Washington University School of Medicine, St Louis, Missouri, United States
10 Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, United States
11 Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, United States
12 The Ohio State University, Columbus, Ohio, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 University of North Carolina, Chapel Hill, North Carolina, United States
15 Dana Farber Cancer Institute, Boston, Massachusetts, United States
16 The Ohio State University, Columbus, Ohio, United States
17 The Ohio State University, Columbus, Ohio, United States
18 Fort Wayne Medical Oncology & Hematology, Fort Wayne, Indiana, United States
19 University of Chicago, Chicago, Illinois, United States
20 Duke University, Durham, North Carolina, United States
21 Mayo Clinic, Rochester, Minnesota, United States
22 University of Pennsylvania, Philadelphia, Pennsylvania, United States
23 University of Calgary, Tom Baker Cancer Centre, Calgary, Alberta, Canada
24 First Health of the Carolinas Cancer Center, Southeast Clinical Oncology Research Consortium, Pinehurst, North Carolina, United States
25 Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
26 Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, United States
27 Alliance Protocol Operations Office, Chicago, Illinois, United States
28 Dana Farber Cancer Institute, Boston, Massachusetts, United States
29 Washington University School of Medicine, St Louis, Missouri, United States
30 University of Chicago, Chicago, Illinois, United States
31 Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota, United States
32 University of Pittsburgh and UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Introduction:

Alliance A041202 (NCT01886872) is an NCI National Clinical Trials Network phase 3 study comparing bendamustine+ rituximab (BR) with ibrutinib (I) and the combination of I+ rituximab (IR) in untreated older CLL pts. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS) and toxicity.  Initial results showed that I-containing regimens had superior PFS to chemoimmunotherapy, and addition of rituximab did not improve PFS over I alone.  Here we present final results from the study.

Pts and Methods:

Eligible pts were ≥ 65 years (yrs) with previously untreated symptomatic CLL.  Pts  were stratified on Rai stage, Zap-70 methylation performed centrally, and del(17)(p13.1) or del(11)(q22.3) by local interphase cytogenetics and were randomized 1:1:1 to each arm.  Pts  on BR who experienced progression could cross over to I. Data were locked on 6/16/2026 for this analysis.

Results:

Between 12/9/2013 and 5/16/2016, 547 pts  were randomized (BR: 183, ibrutinib: 182, IR: 182). Median age was 71 yrs, 53% had unmethylated Zap-70, 61% were IGHV-unmutated (performed in 66% of pts), 6% had del(17p) and 20% del(11q) by central FISH. Stimulated karyotype was performed centrally and revealed ≥ 3 abnormalities (complex) in 27% and ≥ 5 (highly complex) in 11% of pts. Median follow-up for pts still alive is 10 yrs.

Sixty-four pts on the I arm (35.2%) and 50 on the IR arm (27.5%) remain alive and progression-free. Median duration of I was 64 months for both I and IR.  A total of 293 PFS events were reported (BR: 119, I: 80, IR: 94).  Median PFS in BR, I and IR arms was 3.6 yrs (95% CI: 3.2-4.5), 9.7 yrs (95% confidence interval (CI): 7.4-NE), and 8.5 yrs (95% CI: 7.0-9.6), respectively. Both I and IR remained superior to BR in terms of PFS (hazard ratio (HR) of I vs. BR = 0.40; IR vs. BR =0.47, respectively).  Although not statistically significant, pts on the I arm had an improved PFS compared to pts on IR (HR 0.81 (95% CI: 0.60-1.09, p=0.081). PFS was superior in I compared to BR in both the IGHV-unmutated (HR 0.30, 95% CI 0.19-0.48) and IGHV-mutated CLL (HR 0.48, 95% CI 0.27-0.86) subgroups.  PFS was also superior for IR compared to BR (HR 0.49, 95% CI: 0.32-0.76) in IGHV-unmutated CLL, with borderline significance in the IGHV-mutated CLL subgroup (HR 0.63, 95% CI 0.37-1.07).

Pts with TP53 abnormalities had median PFS of 2 yrs (95% CI: 1.2-3.6) with BR, 9.7 yrs (95% CI: 6.3-NE) with I, and 9.3 yrs (95% CI: 7.0-NE) with IR.  Pts with complex karyotype had median PFS of 3.6 yrs (95% CI: 2.1-NE) with BR, NE (95% CI: 9.5-NE) with I, and 9.1 yrs (95% CI: 5.9-NE) with IR.  Pts with highly complex karyotype had median PFS of 1.5 yrs (95% CI: 0.6-6.7) with BR, 6.9 yrs (95% CI: 2.6-NE) with I, and 6.7 yrs (95% CI: 3.9-NE) with IR.

Median OS was not reached in any arm.  There were no significant OS differences among arms, with 10- yr OS rate of 51% for BR (95% CI: 43-59), 61% for I (95% CI: 53-68) and 53% for IR (95% CI: 44-60).

Notable adverse events (AEs) with I include atrial fibrillation or flutter (afib) and hypertension (HTN).  HTN was seen at grade 3 or higher in 22.8% of pts on BR, 38.9% on I and 41.4% on IR. For pts treated with I or IR, 84.8% of these events occurred within the first 4 yrs, 6.2% between yrs 4 and 7, and 7.6% between yrs 7 and10.  Afib (all grades) was observed in 7.2% of pts on the BR arm, 25.6% on I, and 19.9% on IR.  For pts treated with I or IR, 67.1% of the afib events occurred within the first 4 yrs, 14.6% between yrs 4 and 7 and 18.3% during yrs 7-10.

Conclusions:
Final data from A041202 continued to demonstrate superiority of I-containing regimens compared with BR in older pts with treatment-naïve CLL.  With 10 yrs of follow-up, we saw benefit across all pt subgroups, including those with IGHV-mutated disease.  While HTN and afib were more prevalent early, the risk of cardiac AE, particularly afib, remained throughout treatment duration.  There remained no OS difference between arms, which was expected as the study allowed crossover and survival was generally good.  Importantly, median survival had not been reached in any arm, which was significant in a study conducted in older adults, emphasizing the progress that was made in the treatment of CLL over this time period. 

Support: U10CA180821, U10CA180882;
https://acknowledgments.alliancefound.org

Jennifer A. Woyach, MD: Johnson & Johnson - Honoraria; Merck - Honoraria; AbbVie - Honoraria; BeOne - Honoraria; AstraZeneca - Honoraria; Genentech - Honoraria; Loxo@Lilly - Honoraria; Newave - Honoraria; Loxo@Lilly - Research Funding; Merck - Research Funding; Newave - Research Funding; BeOne - Research Funding; AbbVie - Research Funding; Johnson & Johnson - Research Funding; BeOne - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Newave - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Loxo@Lilly - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony)